Importantly, CD8+ T cells responses to SVN have been identified in both cancer patients and in tumor-bearing mice [12], [17], [18], suggesting that immune tolerance to this self-protein is incomplete, which further validates the use of SVN as TAA for subunit vaccines against cancer. This evidence concerns the gene CD8A and neoplasm.